Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Deborah Collyar: What's In It for Patients?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement




Sep
13
Today In Oncology
NeoCOAST 2 Trial Durvalumab Plus Novel Agents May Increase Pathologic Responses in Resectable NSCLC
Using TROP2 Expression to Predict Outcomes in Advanced NSCLC
Perioperative Nivolumab May Improve Event-Free Survival Compared With Neoadjuvant Nivolumab Plus Chemotherapy Alone in Patients With Resectable NSCLC
Study Compares Lung Cancer Screening Triage Protocols
Recurrent High-Grade T1 Bladder Cancer
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Conexiant Oncology Logo